Skip to main content
SpringerLink
Log in

The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres and substantia nigra

  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Summary

In order to investigate the physiological importance of the membrane pump in eliminating released dopamine (DA) we have studied the effects of the putative selective dopamine re-uptake inhibitor, GBR 12909, on synthesis and metabolism of monoamines in the rat striatum, limbic forebrain, cortical hemispheres and substantia nigra (SN). The effects of the drug on the firing rate of catecholamine containing neurons in the SN and locus coerulus (LC) were also investigated. For comparison we have investigated the effects of desipramine and maprotiline. As a measure of the synthesis of noradrenaline (NA), DA and 5-hydroxytryptamine (5-HT) we determined the 3,4-dihydroxyphenylalanine (DOPA) and 5-hydroxytryptophan (5-HTP) accumulation after inhibition of aromatic l-amino acid decarboxylase by 3-hydroxy-benzylhydrazine (NSD 1015). As indirect measurements of DA and NA release in vivo, we have assessed pargyline-induced 3-methoxytyramine (3-MT) and normetanephrine (NM) accumulation and disappearance rates of DA and NA after inhibition of their synthesis by α-methyl-p-tyrosine (α-MT). Administration of GBR 12909 (2.5, 5, 10, 20 or 40 mg/kg) decreased the NSD 1015-induced DOPA accumulation in the striatum and in the limbic forebrain. In contrast, only minor effects of the drug were seen on the DOPA accumulation in the cortical hemisphere and on the cerebral 5-HTP accumulation. GBR 12909 increased the 3-MT accumulation in the striatum, limbic forebrain and the cortical hemispheres, an effect that was even more pronounced in haloperidol-pretreated animals. However, GBR 12909 did not alter the 3-MT accumulation in the SN either when given alone or when given to haloperidol-pretreated rats. In haloperidol-pretreated rats GBR 12909 markedly enhanced the DA disappearance in the striatum and in the limbic forebrain, but not in the SN. Furthermore, GBR 12909 did not significantly affect the firing rate of dopaminergic neurons in the SN or that of noradrenergic neurons in the LC. Taken together, our results support the notion that GBR 12909 is a specific DA uptake inhibitor without a transmitter releasing action. In addition, our findings indicate that DA re-uptake is of physiological importance in the elimination of DA from the synaptic cleft in the striatum, limbic forebrain and cortical hemispheres, but not in the SN. Furthermore, a large part of the DA taken up by the dopaminergic terminals in the striatum and in the limbic forebrain seems to be re-incorporated into the storage vesicles.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aghajanian GK, Cederbaum JW, Wang R (1977) Evidence for norepinephrine-mediated collateral inhibition of locus coeruleus neurons. Brain Res 136:570–577

    Google Scholar 

  • Andén N-E (1980) Regulation of monoamine synthesis and utilization by receptors. In: Szekeres L (ed) Handbook of experimental pharmacology, vol 27. Springer-Verlag, Berlin Heidelberg New York, pp 429–462

    Google Scholar 

  • Andersen PH (1989) The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol 166:493–504

    Google Scholar 

  • Annunziato L (1979) Regulation of the tuberoinfundibular and nigrostriatal systems. Neuroendocrinol 29:66–76

    Google Scholar 

  • Anton AH, Sayre DF (1962) A study of the factors affecting the aluminum oxidetrihydroxyindole procedure for the analysis of catecholamines. J Pharmacol Exp Ther 138:360–375

    Google Scholar 

  • Bunney BS, Aghajanian GK (1978) d-Amphetamine-induced depression of central dopaminergic neurons: Evidence for mediation by both autoreceptors and a striato-nigral feed-back pathway. Naunyn-Schmiedeberg's Arch Pharmacol 304:255–261

    Google Scholar 

  • Bunney BS, Aghajanian GK, Roth RH (1973) Comparison of effects of L-DOPA, amphetamine and apomorphine on firing rate of rat dopaminergic neurones. Nature 245:123–125

    Google Scholar 

  • Carlsson A, Lindqvist M (1973) Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo. J Pharm Pharmacol 25:437–440

    Google Scholar 

  • Carlsson A, Lindqvist M (1978) Effects of antidepressant agents on the synthesis of brain monoamines. J Neural Transm 43:73–91

    Google Scholar 

  • Carlsson A, Davis JN, Kehr W, Lindqvist M, Atack CV (1972) Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo using an inhibitor of the aromatic amino decarboxylase. Naunyn-Schmiedeberg's Arch Pharmacol 275:153–168

    Google Scholar 

  • Cella S, Apud J, Racagni G, Müller EE (1982) Dopamine reuptake inhibitors and dopamine releasers: differential effect on plasma prolactin in the rat. Pharmacological Res Com 14:839–849

    Google Scholar 

  • Dawson TM, Gehlert DR, Wamsley JK (1986) Quantitative autoradiographic localization of the dopamine transport complex in the rat brain: use of a highly selective radioligand: [3H]GBR 12935. Eur J Pharmacol 126:171–173

    Google Scholar 

  • Demarest KT, Moore KE (1979) Lack of a high affinity transport system for dopamine in the median eminence and posterior pituitary. Brain Res 171:545–551

    Google Scholar 

  • Engberg G, Svensson TH (1979) Amphetamine-induced inhibition of central noradrenergic neurons: a pharmacological analysis. Life Sci 24:2245–2254

    Google Scholar 

  • Ewing AG, Wightman RM (1984) Monitoring the stimulated release of dopamine with in vivo voltammetry. II. Clearance of released dopamine from extracellular fluid. J Neurochem 43:570–577

    Google Scholar 

  • Felice LJ, Felice JD, Kissinger P (1978) Determination of catecholamines in rat brain parts by reverse-phase ion-pair liquid chromatography. J Neurochem 31:1461–1465

    Google Scholar 

  • Folkow B, Häggendal J, Lisander B (1967) Extent of release and elimination of noradrenaline at peripheral adrenergic nerve terminals. Acta Physiol Scand Suppl 307:1–38

    Google Scholar 

  • Fornstedt B, Carlsson A (1989) A marked rise in 5-S-cysteinyldopamine levels in guinea-pig striatum following reserpine treatment. J Neural Transm 76:155–161

    Google Scholar 

  • Fuller FW, Snoddy HD (1979) Effect of mazindol on brain dopamine turnover in spiperone-treated rats. J Neural Transm 44:13–19

    Google Scholar 

  • Garcia-Sevilla JA, Ahtee L, Magnusson T, Carlsson A (1978) Opiate-receptor mediated changes in monoamine synthesis in rat brain. J Pharm Pharmacol 30:613–621

    Google Scholar 

  • German DC, Harden H, Sanghera MK, Mann D, Kiser RS, Miller H, Shore PA (1979) Dopaminergic neuronal responses to a non-amphetamine CNS stimulant. J Neural Transm 44:39–49

    Google Scholar 

  • Grace AA, Bunney BS (1983) Intracellular and extracellular electrophysiology of nigral dopaminergic neurons — 1. Identification and characterization. Neurosci 10:301–315

    Google Scholar 

  • Graham DG (1984) Catecholamine Toxicity: A proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. Neurotoxical 5:83–96

    Google Scholar 

  • Hardy JA, Wester P, Backstrom I, Gottfries J, Oreland L, Stenström A, Winblad B (1987) The regional distribution of dopamine and serotonin uptake and transmitter concentrations in the human brain. Neurochem Int 10:445–450

    Google Scholar 

  • Heikkila R, Manzino L (1984) Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake. Eur J Pharmacol 103:241–248

    Google Scholar 

  • Hurd YL, Ungerstedt U (1989) Ca2+-dependence of the amphetamine, nomifensine, and Lu 19–005 effect on in vivo dopamine transmission. Eur J Pharmacol 166:261–269

    Google Scholar 

  • Iversen LL (1975) Uptake processes for biogenic amines. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of Psychopharmacology, vol 3. Plenum Press, New York, pp 381–442

    Google Scholar 

  • Kaplan GP, Hartman BK, Creveling CR (1979) Immuno-istochemical demonstration of catechol-O-methyltransferase in mammalian brain. Brain Res 167:241–250

    Google Scholar 

  • Kehr W (1981) 3-Methoxytyramine and normetanephrine as indicators of dopamine and noradrenaline release in mouse brain in vivo. J Neural Transm 50:165–178

    Google Scholar 

  • Kehr W, Speckenbach W, Zimmermann R (1977) Interaction of haloperidol and y-butyrolactone with (+)-amphetamine-induced changes in monoamine synthesis and metabolism in rat brain. J Neural Transm 40:129–147

    Google Scholar 

  • Kelley AE, Lang GG (1989) Effects of GBR 12909, a selective dopamine uptake inhibitor, on motor activity and operant behavior in the rat. Eur J Pharmacol 167:385–395

    Google Scholar 

  • Kelly RS, Wightman RM (1987) Detection of dopamine overflow and diffusion with voltammetry in slices of rat brain. Brain Res 423:79–87

    Google Scholar 

  • Magnusson O, Nilsson LB, Westerlund D (1980) Simultaneous determination of dopamine, DOPAC and homovanillic acid. Direct injection of supernatants from brain tissue homogenates in a liquid chromatography-electrochemical detection system. J Chromatogr 221:237–247

    Google Scholar 

  • Marcusson J, Eriksson K (1988) [3H]GBR-12935 binding to dopamine uptake sites in the human brain. Brain Res 457:122–129

    Google Scholar 

  • Markwell MAK, Haas SM, Bieber LL, Tolbert NE (1978) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 87:206–210

    Google Scholar 

  • McMillen BA (1983) CNS stimulants: two distinct mechanisms of action for amphetamine-like drugs. Trends Pharmacol Sci 4:429–432

    Google Scholar 

  • Moldéus P, Nordenskjöld M, Bolcsfoldi G, Haglund U, Lambert B (1983) Genetic toxicity of dopamine. Mutat Res 124:9–24

    Google Scholar 

  • Nagase T, Ishiko J, Takaori S (1987) Effects of 1-[2-[bis(fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl) piperazine dihydrochloride (I-893) on turnover of dopamine and norepinephrine in the brain. Folia Pharmacol Japon 90:105–114

    Google Scholar 

  • Nissbrandt H (1988) Dopamine synthesis, release and metabolism in rat substantia nigra. Thesis, University of Göteborg

  • Nissbrandt H, Carlsson A (1987) Turnover of dopamine and dopamine metabolites in rat brain: comparison between striatum and substantia nigra. J Neurochem 49:959–967

    Google Scholar 

  • Nissbrandt H, Sundström E, Jonsson G, Hjorth S, Carlsson A (1989) Synthesis and release of dopamine in rat brain. Comparison between substantia nigra pars compacta, pars reticulata and striatum. J Neurochem 52:1170–1182

    Google Scholar 

  • Oreland L, Lundberg P-Å, Engberg G (1985) Effects of 2-phenylethylamine and tyramine on central noradrenaline and dopamine systems: an electro-physiological study. In: Boulton AA, Bieck PR, Maitre L, Riederer P (eds) Neuropharmacology of the trace amines. Experimental and clinical aspects, Humana Press, Clifton New Jersey, pp 201–212

    Google Scholar 

  • Pileblad E, Carlsson A (1985) Catecholamine-uptake inhibitors prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain. Neuropharmacol 24:689–692

    Google Scholar 

  • Pileblad E, Engberg G (1986) GBR 13098, a selective dopamine uptake inhibitor; behavioural, biochemical and electrophysiological studies. Naunyn-Schmiedeberg's Arch Pharmacol 334:383–387

    Google Scholar 

  • Rebec GV, Segal DS (1978) Dose-dependent biphasic alterations in the spontaneous activity of neurons in the rat neostriatum produced by d-amphetamine and methylphenidate. Brain Res 150:353–366

    Google Scholar 

  • Richelson E, Pfenning M (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104:277–286

    Google Scholar 

  • Shore PA (1976) Actions of amfonelic acid and other non-amphetamine stimulants on the dopamine neuron. J Pharm Pharmacol 28:855–857

    Google Scholar 

  • Stamford JA, Kruz ZL, Millar J, Wightman RM (1984) Striatal dopamine uptake in the rat: in vivo analysis by fast cyclic voltammetry. Neurosci Lett 51:133–138

    Google Scholar 

  • Studer A, Schultz W (1987) The catecholamine uptake inhibitor nomifensine depresses impulse activity of dopamine neurons in mouse substantia nigra. Neurosci Lett 80:207–212

    Google Scholar 

  • Tanner CM (1989) The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurol Sci 12:49–54

    Google Scholar 

  • Tasaki K, Tsukahara U, Ito S, Wayner MJ, Yu WY (1968) A simple, direct and rapid method for filling micorelectrodes. Physiol Behav 3:1009–1010

    Google Scholar 

  • Van Der Zee P, Koger HS, Gootjes J, Hespe W (1980) Aryl 1,4-dialk(en)yl-piperazines as selective and very potent inhibitors of dopamine uptake. Eur J Med Chem 15:363–370

    Google Scholar 

  • Westerink BHC, Damsma G, De Vries JB, Koning H (1987a) Dopamine re-uptake inhibitors show inconsistent effects on the in vivo release of dopamine as measured by intracerebral dialysis in the rat. Eur J Pharmacol 135:123–128

    Google Scholar 

  • Westerink BHC, Tuntler J, Damsma G, Rollema H, de Vries JB (1987b) The use of tetrodotoxin for the characterization of drug-enhanced dopamine release in conscious rats studied by brain dialysis. Naunyn-Schmiedeberg's Arch Pharmacol 336:502–507

    Google Scholar 

  • Westerink BHC, Hofsteede HM, Rollema H, de Vries JB (1988) The significance of extracellular calcium for the release of dopamine, acetylcholine and amino acids in conscious rats, evaluated by brain microdialysis. Naunyn-Schmiedeberg's Arch Pharmacol 337:373–378

    Google Scholar 

  • Wolf ME, Roth RH (1987) Dopamine autoreceptors. In: Creese I, Fraser CM (eds) Dopamine receptors, Alan R Liss Inc, New York, pp 45–96

    Google Scholar 

  • Wood PL, Altar CA (1988) Dopamine release in vivo from nigrostriatal, mesolimbic and mesocortical neurons: utility of 3-methoxytyramine measurements. Pharmacol Rev 40:163–187

    Google Scholar 

  • Woodward JJ, Wilcox RE, Leslie SW, Riffee WH (1986) Dopamine uptake during fast-phase endogenous dopamine release from mouse striatal synaptosomes. Neurosci Lett 71:106–112

    Google Scholar 

  • Yoshida M, Precht W (1971) Monosynaptic inhibition of neurons of the substantia nigra by caudate-nigral fibers. Brain Res 32:225–228

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, University of Göteborg, P. O. Box 33031, S-40033, Göteborg, Sweden

    H. Nissbrandt, G. Engberg & E. Pileblad

Authors
  1. H. Nissbrandt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Engberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Pileblad
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Send offprint requests to H. Nissbrandt at the above address

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nissbrandt, H., Engberg, G. & Pileblad, E. The effects of GBR 12909, a dopamine re-uptake inhibitor, on monoaminergic neurotransmission in rat striatum, limbic forebrain, cortical hemispheres and substantia nigra. Naunyn-Schmiedeberg's Arch Pharmacol 344, 16–28 (1991). https://doi.org/10.1007/BF00167378

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00167378

Key words

Search

Navigation